Chimeric Antigen Receptor (CAR)  T cell immunotherapy has revolutionized how we treat blood cancers such as B cell leukemias. While this new therapy can be highly effective, cancers often recur.

To understand mechanisms of treatment failure, Hemann Lab researchers are investigating the dynamic interactions between CAR-T cells and B cell malignancies, using microscopy to gain insight into how cancer cells evade or succumb to CAR-T therapy. Here a CAR-T cell (green) attaches to and destroys a leukemia cell (red).